252
Participants
Start Date
November 12, 2013
Primary Completion Date
March 14, 2016
Study Completion Date
March 14, 2016
Sham injection
Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
Ranibizumab 0.5 mg
Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
Novartis Investigative Site, Manila
Novartis Investigative Site, San Juan City
Novartis Investigative Site, Hanoi
Novartis Investigative Site, Jakarta
Novartis Investigative Site, Linkou District
Novartis Investigative Site, Bandung
Novartis Investigative Site, Ho Chi Minh City
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Harbin
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Nantong
Novartis Investigative Site, Qingdao
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Wenzhou
Novartis Investigative Site, Nanchang
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Shantou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Taipei
Novartis Investigative Site, Ahmedabad
Novartis Investigative Site, Bhubaneswar
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY